Bonesupport Holding AB Cash Flow Conversion Efficiency
Bonesupport Holding AB cash flow conversion efficiency. Based on the latest financial reports, Bonesupport Holding AB (BONEX) has a cash flow conversion efficiency ratio of 0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr71.09 Million ≈ $7.65 Million USD) by net assets (Skr835.89 Million ≈ $89.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bonesupport Holding AB (BONEX) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Bonesupport Holding AB (2014–2024)
Cash flow conversion efficiency of Bonesupport Holding AB from 2014 to 2024. This chart illustrates how Bonesupport Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bonesupport Holding AB (BONEX) share price today for real-time trading data and today's change.
Bonesupport Holding AB Cash Flow Conversion Ratio Explained
Bonesupport Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bonesupport Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bonesupport Holding AB ranked by their cash flow conversion efficiency. Review Bonesupport Holding AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
0.101x |
|
Wallenstam AB (publ)
ST:WALL-B
|
0.011x |
|
Lotus Health Group Co
SHG:600186
|
0.043x |
|
Douzone Bizon Co Ltd
KO:012510
|
0.036x |
|
Insignia Financial Ltd
AU:IFL
|
0.091x |
|
Zhuzhou Hongda Electronics Corp Ltd Class A
SHE:300726
|
-0.001x |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
0.119x |
|
LEROY SEAFOOD GR.UNSP.ADR
F:Z1L0
|
0.031x |
Annual Cash Flow Conversion Efficiency for Bonesupport Holding AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of Bonesupport Holding AB from 2014 to 2024. Also see Bonesupport Holding AB total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr727.46 Million ≈ $78.29 Million |
Skr65.76 Million ≈ $7.08 Million |
0.090x | +369.93% |
| 2023-12-31 | Skr545.18 Million ≈ $58.67 Million |
Skr-18.26 Million ≈ $-1.96 Million |
-0.033x | +80.83% |
| 2022-12-31 | Skr268.93 Million ≈ $28.94 Million |
Skr-46.98 Million ≈ $-5.06 Million |
-0.175x | +44.35% |
| 2021-12-31 | Skr265.70 Million ≈ $28.59 Million |
Skr-83.42 Million ≈ $-8.98 Million |
-0.314x | -24.90% |
| 2020-12-31 | Skr398.90 Million ≈ $42.93 Million |
Skr-100.28 Million ≈ $-10.79 Million |
-0.251x | +80.93% |
| 2019-12-31 | Skr124.31 Million ≈ $13.38 Million |
Skr-163.83 Million ≈ $-17.63 Million |
-1.318x | -113.88% |
| 2018-12-31 | Skr278.53 Million ≈ $29.97 Million |
Skr-171.62 Million ≈ $-18.47 Million |
-0.616x | -158.30% |
| 2017-12-31 | Skr450.79 Million ≈ $48.51 Million |
Skr-107.53 Million ≈ $-11.57 Million |
-0.239x | +90.01% |
| 2016-12-31 | Skr34.30 Million ≈ $3.69 Million |
Skr-81.93 Million ≈ $-8.82 Million |
-2.388x | +25.64% |
| 2015-12-31 | Skr20.33 Million ≈ $2.19 Million |
Skr-65.29 Million ≈ $-7.03 Million |
-3.212x | -404.36% |
| 2014-12-31 | Skr-43.52 Million ≈ $-4.68 Million |
Skr-45.92 Million ≈ $-4.94 Million |
1.055x | -- |
About Bonesupport Holding AB
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin duri… Read more